MENLO PARK, Calif.--(BUSINESS WIRE)--SwitchGear Genomics Inc., a leading provider of products for studying the regulatory elements in the human genome, today announced the availability of the industry’s first cost-effective high-throughput research tool for screening the transcriptional activation in the nuclear receptor and hypoxia gene pathways. The Nuclear Receptor Pathway Set™ and Hypoxia Pathway Set™ enable researchers to independently measure the impact of a stimulus on the transcriptional activation of each gene in a regulatory network.
